MA47074A - Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires - Google Patents
Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoiresInfo
- Publication number
- MA47074A MA47074A MA047074A MA47074A MA47074A MA 47074 A MA47074 A MA 47074A MA 047074 A MA047074 A MA 047074A MA 47074 A MA47074 A MA 47074A MA 47074 A MA47074 A MA 47074A
- Authority
- MA
- Morocco
- Prior art keywords
- task
- treatment
- dosage forms
- respiratory disorders
- channel inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16205688.1A EP3338764A1 (fr) | 2016-12-21 | 2016-12-21 | Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires |
| EP17157805 | 2017-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47074A true MA47074A (fr) | 2021-04-14 |
Family
ID=60857052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047074A MA47074A (fr) | 2016-12-21 | 2017-12-13 | Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20200093737A1 (fr) |
| EP (1) | EP3558380A1 (fr) |
| JP (1) | JP2020502215A (fr) |
| KR (1) | KR20190099245A (fr) |
| CN (1) | CN110290809A (fr) |
| AU (1) | AU2017379245A1 (fr) |
| BR (1) | BR112019012836A2 (fr) |
| CA (1) | CA3047426A1 (fr) |
| CL (1) | CL2019001726A1 (fr) |
| CO (1) | CO2019006642A2 (fr) |
| CR (1) | CR20190299A (fr) |
| CU (1) | CU20190063A7 (fr) |
| DO (1) | DOP2019000172A (fr) |
| EC (1) | ECSP19044577A (fr) |
| IL (1) | IL267503A (fr) |
| JO (1) | JOP20190148A1 (fr) |
| MA (1) | MA47074A (fr) |
| MX (1) | MX2019007619A (fr) |
| PE (1) | PE20191240A1 (fr) |
| PH (1) | PH12019501458A1 (fr) |
| TW (1) | TW201834653A (fr) |
| UY (1) | UY37541A (fr) |
| WO (1) | WO2018114501A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180088462A (ko) | 2015-12-10 | 2018-08-03 | 바이엘 파마 악티엔게젤샤프트 | 수면-관련 호흡기 장애의 치료를 위한 TASK-1 및 TASK-2 채널의 차단제로서의 2-페닐-3-(피페라지노메틸)이미다조[1,2-a]피리딘 유도체 |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為malt1抑制劑之吡唑衍生物 |
| JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| CN112585128B (zh) | 2018-06-18 | 2023-02-21 | 詹森药业有限公司 | 作为malt1抑制剂的吡唑衍生物 |
| GEP20247606B (en) | 2018-11-27 | 2024-03-11 | Bayer Ag | Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy |
| EP3953345B1 (fr) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Dérivés de pyridines comme inhibiteurs de malt1 |
| KR102637904B1 (ko) * | 2020-07-01 | 2024-02-19 | 주식회사 뉴캔서큐어바이오 | 3-케토아실 CoA 타이올레이스 억제제 및 카르니틴 아실카르니틴 운반자 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| US6080783A (en) * | 1998-09-01 | 2000-06-27 | Gum Tech International, Inc. | Method and composition for delivering zinc to the nasal membrane |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| KR101390239B1 (ko) * | 2006-04-27 | 2014-04-30 | 사노피-아벤티스 도이칠란트 게엠베하 | Task-1 및 task-3 이온 채널 억제제 |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| PH12013500055A1 (en) | 2010-07-09 | 2017-08-23 | Bayer Ip Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
| US9132243B2 (en) | 2010-07-23 | 2015-09-15 | Tannermedico A/S | Method of administering a substance to the throat |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| CN103877288B (zh) * | 2014-04-16 | 2016-01-20 | 广西信业生物技术有限公司 | 一种壳聚糖鼻咽生物医用膜及其制备方法 |
-
2017
- 2017-06-16 JO JOP/2019/0148A patent/JOP20190148A1/ar unknown
- 2017-12-13 CA CA3047426A patent/CA3047426A1/fr not_active Abandoned
- 2017-12-13 CU CU2019000063A patent/CU20190063A7/es unknown
- 2017-12-13 EP EP17822216.2A patent/EP3558380A1/fr not_active Withdrawn
- 2017-12-13 KR KR1020197020701A patent/KR20190099245A/ko not_active Withdrawn
- 2017-12-13 MA MA047074A patent/MA47074A/fr unknown
- 2017-12-13 US US16/472,116 patent/US20200093737A1/en not_active Abandoned
- 2017-12-13 AU AU2017379245A patent/AU2017379245A1/en not_active Abandoned
- 2017-12-13 MX MX2019007619A patent/MX2019007619A/es unknown
- 2017-12-13 WO PCT/EP2017/082542 patent/WO2018114501A1/fr not_active Ceased
- 2017-12-13 PE PE2019001285A patent/PE20191240A1/es unknown
- 2017-12-13 CN CN201780086896.1A patent/CN110290809A/zh active Pending
- 2017-12-13 JP JP2019533535A patent/JP2020502215A/ja active Pending
- 2017-12-13 CR CR20190299A patent/CR20190299A/es unknown
- 2017-12-13 BR BR112019012836A patent/BR112019012836A2/pt not_active Application Discontinuation
- 2017-12-19 TW TW106144527A patent/TW201834653A/zh unknown
- 2017-12-21 UY UY0001037541A patent/UY37541A/es not_active Application Discontinuation
-
2019
- 2019-06-19 DO DO2019000172A patent/DOP2019000172A/es unknown
- 2019-06-19 IL IL267503A patent/IL267503A/en unknown
- 2019-06-20 CL CL2019001726A patent/CL2019001726A1/es unknown
- 2019-06-21 CO CONC2019/0006642A patent/CO2019006642A2/es unknown
- 2019-06-21 EC ECSENADI201944577A patent/ECSP19044577A/es unknown
- 2019-06-21 PH PH12019501458A patent/PH12019501458A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3558380A1 (fr) | 2019-10-30 |
| CO2019006642A2 (es) | 2019-09-18 |
| WO2018114501A1 (fr) | 2018-06-28 |
| TW201834653A (zh) | 2018-10-01 |
| PH12019501458A1 (en) | 2020-06-01 |
| BR112019012836A2 (pt) | 2019-12-17 |
| JP2020502215A (ja) | 2020-01-23 |
| CN110290809A (zh) | 2019-09-27 |
| MX2019007619A (es) | 2019-09-06 |
| AU2017379245A1 (en) | 2019-07-11 |
| UY37541A (es) | 2018-07-31 |
| CR20190299A (es) | 2019-09-04 |
| DOP2019000172A (es) | 2019-07-15 |
| US20200093737A1 (en) | 2020-03-26 |
| CA3047426A1 (fr) | 2018-06-28 |
| PE20191240A1 (es) | 2019-09-16 |
| JOP20190148A1 (ar) | 2019-06-18 |
| ECSP19044577A (es) | 2019-06-30 |
| KR20190099245A (ko) | 2019-08-26 |
| CU20190063A7 (es) | 2020-02-04 |
| CL2019001726A1 (es) | 2019-11-29 |
| IL267503A (en) | 2019-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47069A (fr) | Formes pharmaceutiques contenant des inhibiteurs des canaux task-1 et task-3 et leur utilisation pour le traitement de troubles respiratoires | |
| MA47074A (fr) | Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires | |
| EP3481387A4 (fr) | Methodes et compositions pour le traitement de troubles épileptiques | |
| MA50082A (fr) | Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer | |
| EP3448398A4 (fr) | Compositions et méthodes pour le traitement de troubles cutanés | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| EP3484577A4 (fr) | Procédés et systèmes de traitement de troubles pelviens et d'affections douloureuses | |
| EP3727405A4 (fr) | Composition comprenant du lactobacillus plantarum pour la prévention et/ou le traitement de troubles mentaux | |
| EP3328376A4 (fr) | Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique | |
| EP3370748A4 (fr) | Microbiote thérapeutique pour le traitement et/ou la prévention de l'allergie alimentaire | |
| EP3180022A4 (fr) | Cassette d'expression améliorée pour le conditionnement et l'expression de variantes du facteur viii pour le traitement des troubles de l'hémostase | |
| EP3468532A4 (fr) | Dispositif de distribution et composition pharmaceutique pour le traitement de la rhinite | |
| FR3032353B1 (fr) | Composition pharmaceutique et dispositif pour le traitement de la douleur | |
| EP3307754A4 (fr) | Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles de la peau | |
| MA49368A (fr) | Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires | |
| EP3735970C0 (fr) | Cébranopadol pour le traitement de la douleur chez des sujets à fonction hépatique altérée et/ou fonction rénale altérée | |
| EP2970099A4 (fr) | Dérivés de 3-phénylpropylamine substitués pour le traitement des maladies et des troubles ophtalmiques | |
| EP3328864A4 (fr) | Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie | |
| EP3348643A4 (fr) | Interleukine 12 modifiée et utilisation de celle-ci dans la préparation de médicaments pour le traitement de tumeurs | |
| MA49794A (fr) | Composition utilisée dans le traitement prophylactique et thérapeutique de troubles de l'appareil cardiovasculaire | |
| EP3362096A4 (fr) | Composition de traitement ophtalmique et véhicule pour l'administration de substances pharmaceutiques ou d'agents thérapeutiques | |
| EP2999444A4 (fr) | Système thérapeutique transdermique pour dosage à libération prolongée de pramipexole dans le traitement de troubles neurologiques | |
| EP3848022C0 (fr) | Agent thérapeutique pour utilisation dans le traitement d'infections | |
| EP3831821A4 (fr) | Composé pour le traitement de maladies du système nerveux et utilisation associée | |
| EP3442554A4 (fr) | Compositions et méthodes pour le traitement de troubles associés à la néovascularisation |